Your browser doesn't support javascript.
loading
Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer.
Ruan, Guo-Tian; Xie, Hai-Lun; Zhang, He-Yang; Zhang, Qi; Deng, Li; Wang, Zi-Wen; Zhang, Xi; Ge, Yi-Zhong; Hu, Chun-Lei; Tang, Meng; Song, Meng-Meng; Zhang, Xiao-Wei; Liu, Tong; Li, Xiang-Rui; Zhang, Kang-Ping; Yang, Ming; Gong, Yi-Zhen; Chen, Yong-Bing; Yu, Kai-Ying; Cong, Ming-Hua; Pan, Lei; Tang, Wei-Zhong; Wang, Kun-Hua; Shi, Han-Ping.
Afiliação
  • Ruan GT; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Xie HL; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Zhang HY; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Zhang Q; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Deng L; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Wang ZW; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Zhang X; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Ge YZ; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Hu CL; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Tang M; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Song MM; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Zhang XW; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Liu T; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Li XR; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Zhang KP; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Yang M; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Gong YZ; Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region 530021, PR China; Guangxi Clinical Research Center for Colorectal Cancer, Nanning, Guangxi Zhuang Autonomous Region 530021, PR China.
  • Chen YB; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Yu KY; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.
  • Cong MH; Comprehensive Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100038, PR China.
  • Pan L; Department of Respiratory and Critical Care Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, PR China.
  • Tang WZ; Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region 530021, PR China; Guangxi Clinical Research Center for Colorectal Cancer, Nanning, Guangxi Zhuang Autonomous Region 530021, PR China. Electronic address: tangweizhong@gxmu.ed
  • Wang KH; Yunnan University, Kunming, 650091, PR China; General Surgery Clinical Medical Center of Yunnan Province, Kunming, 650032, PR China. Electronic address: kunhuawang1@163.com.
  • Shi HP; Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China. Electronic address: shihp@ccmu.edu.cn.
Clin Nutr ; 41(10): 2284-2294, 2022 10.
Article em En | MEDLINE | ID: mdl-36096062
BACKGROUND: Inflammation is involved in the progression and prognosis of cancer because it can affect the physical status and prognosis of patients. Among numerous systemic inflammatory markers, the optimal prognostic indicator of older adults with cancer is still unclear. We aimed to identify an ideal inflammatory immune marker in older adults with cancer and assess the survival outcome combined with eastern cooperative oncology group performance status (ECOG PS). METHODS: We included 1767 older adults with cancer (66.2% males, 70.97 ± 5.49 years old) from a prospective cohort study. Fifteen systemic inflammatory biomarkers were compared to identify the optimal biomarker using prognostic area under the curve (AUC) and concordance index (C-index) analysis. The prognostic value of the clinical parameters was elucidated by performing uni- and multivariate analyses. RESULTS: The AUC, C-index, and the subgroup survival analysis of ECOG PS groups showed that the lymphocyte-C reactive protein ratio (LCR) and C-reactive protein/albumin ratio (CAR) were more accurate in reflecting patient prognosis than the other 13 inflammatory markers. Compared with patients in the high LCR group, those in the low LCR group had worse survival (hazard ratio (HR) 1.64, 95% confidence interval (95%CI) 1.42-1.91, p < 0.001). Compared with patients in the low CAR group, those in the high CAR group had worse survival (HR 1.65, 95% CI 1.43-1.91, p < 0.001). Older adults with cancer with an ECOG PS score of 2 or 3-4 and a high inflammation (low LCR, 13.3 months and 9.2 months, respectively; or high CAR, 9.6 months and 9.6 months, respectively) had shorter median survival time compared to those with an ECOG PS score of 0/1 and a low inflammation (high LCR, 77.4 months; or low CAR, 77.0 months). CONCLUSION: LCR and CAR might be the better predictive immune inflammatory factors for OS, which improved the survival prediction of different ECOG PS groups in older adults with cancer. High ECOG PS (≥2) and high inflammation increased the risk of death in older adults with cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína C-Reativa / Neoplasias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína C-Reativa / Neoplasias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article